PULMONARY ARTERIAL HYPERTENSION (PAH)

This study tests an experimental drug called REGN13335 in 99 adults with pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lungs makes the heart work harder. Participants will receive either the drug or a placebo, on top of their usual PAH medica…

This phase 1 trial tests the safety of a new drug called ZMA001 in 96 healthy adults. ZMA001 is a monoclonal antibody designed to reduce lung damage in pulmonary arterial hypertension (PAH), a serious condition. Participants receive a single dose of the drug or placebo and are mo…

This study tests an experimental oral drug called ROC-101 in 40 adults with pulmonary arterial hypertension (PAH) or pulmonary hypertension linked to interstitial lung disease (ILD-PH). Participants take the drug alongside their standard care for 24 weeks, with a long-term follow…

This study tests an investigational drug called IMC-003 in 120 adults with pulmonary arterial hypertension (PAH), a serious lung condition that makes the heart work harder. Participants receive multiple injections of the drug or a placebo, alongside their usual treatments. The go…

This study compares starting with two oral medications (tadalafil and ambrisentan) versus one medication alone in people newly diagnosed with pulmonary arterial hypertension (PAH) who also have at least two heart-related conditions. The goal is to see if the two-drug approach lea…

This early-stage study is testing whether artesunate, a drug used for malaria, is safe for people with pulmonary arterial hypertension (PAH). Fifteen adults with PAH will take increasing doses of artesunate capsules for 20 weeks. The main goal is to check for side effects, not ye…

This study tests whether extra guidance from a pharmacist can help people with pulmonary arterial hypertension (PAH) use their inhaled iloprost correctly and consistently. PAH is a rare, serious lung condition that makes it hard to breathe. The trial will enroll 72 adults who alr…

This study tests whether the drug sotatercept can improve right heart function in people with pulmonary arterial hypertension (PAH). PAH causes high blood pressure in the lungs, straining the right side of the heart. Sotatercept targets the underlying blood vessel changes, not ju…

This study tests whether a home rehabilitation program using daily text or email messages with simple exercises can reduce the number of heartbeats needed during a 6-minute walk in people with pulmonary arterial hypertension (PAH). Researchers will enroll 55 adults with PAH and c…

This study is creating and testing a questionnaire called SAVOIR to measure how much people with pulmonary arterial hypertension (PAH) understand about their condition. Up to 215 patients and expert judges will help ensure the questions are clear, relevant, and reliable. The goal…

This study looks at how long it takes for people in Brazil to get a correct diagnosis of pulmonary arterial hypertension (PAH), a rare and serious lung disease. Researchers will review medical records of about 139 adults diagnosed in the last five years to find out what causes de…

This study looks at what happens when people with pulmonary arterial hypertension (PAH) switch from one medication (ambrisentan) to another (bosentan). Researchers will track 121 adults to see if their risk level, symptoms, and side effects change after the switch. The goal is to…